- List
- By Topic
- On Map
- Search Details

testicular cancer | Recruiting, Not yet recruiting, Available Studies | Studies Without Results | Interventional Studies | Adult
Need help? See RSS Feeds
Choose a feed type:

testicular cancer | Recruiting, Not yet recruiting, Available Studies | Studies Without Results | Interventional Studies | Adult (48 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03339635 | Not yet recruiting | Short-term Testosterone Replacement in Testicular Cancer Survivors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
40 | Male | 18 Years to 55 Years (Adult) | NCT03339635 | 201600107 | December 2018 | July 2020 | July 2020 | November 13, 2017 | November 9, 2018 |
|
|||
2 | NCT02341989 | Recruiting | Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
348 | Male | 18 Years to 60 Years (Adult) | NCT02341989 | 2014/2012 2014-004075-23 |
SWENOTECA-ABC | April 8, 2015 | December 2020 | December 2020 | January 19, 2015 | November 5, 2018 |
|
||
3 | NCT03360994 | Recruiting | WATChmAN Virtual Testicular Cancer Clinic |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
144 | Male | 18 Years and older (Adult, Older Adult) | NCT03360994 | 17-5366 | December 15, 2017 | December 1, 2024 | December 1, 2024 | December 4, 2017 | December 29, 2017 |
|
|||
4 | NCT03436901 | Recruiting | Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
78 | Male | 18 Years and older (Adult, Older Adult) | NCT03436901 | VEK RM 1-10-72-179-17 | TENY | February 19, 2018 | September 2020 | September 2020 | February 19, 2018 | February 22, 2018 |
|
||
5 | NCT02991209 | Recruiting | Study of Testosterone vs Placebo in Testicular Cancer Survivors |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
70 | Male | 18 Years to 65 Years (Adult, Older Adult) | NCT02991209 | 010815Testis | Einstein | November 2016 | August 2019 | December 2019 | December 13, 2016 | January 11, 2017 |
|
||
6 | NCT02860819 | Recruiting | Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
43 | Male | 18 Years and older (Adult, Older Adult) | NCT02860819 | GCTSK004 | July 2016 | December 2018 | December 2018 | August 9, 2016 | August 22, 2018 |
|
|||
7 | NCT02478502 | Recruiting | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
29 | Male | 18 Years and older (Adult, Older Adult) | NCT02478502 | 2012/1627 b 2012-004418-32 |
June 2015 | June 2019 | June 2019 | June 23, 2015 | November 5, 2018 |
|
|||
8 | NCT02433197 | Recruiting | Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 18 Years to 45 Years (Adult) | NCT02433197 | FCCSS-UMA_04-15 | EFICATEST | December 2015 | April 2016 | December 2017 | May 4, 2015 | March 31, 2017 |
|
||
9 | NCT03426865 | Recruiting | Role of Axumin PET Scan in Germ Cell Tumor |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
10 | Male | 18 Years and older (Adult, Older Adult) | NCT03426865 | 032017-051 | TESTPET | March 1, 2018 | May 30, 2019 | May 30, 2019 | February 8, 2018 | January 31, 2019 |
|
||
10 | NCT02853006 | Recruiting | Study on Fluids Associated to Lung Cancer |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
200 | All | 18 Years and older (Adult, Older Adult) | NCT02853006 | 38RC15.099 | ECTOPIC/MUTAS | June 2015 | June 2019 | June 2019 | August 2, 2016 | August 2, 2016 |
|
||
11 | NCT03709706 | Recruiting | Pilot Immunotherapy With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
44 | All | 18 Years and older (Adult, Older Adult) | NCT03709706 | 208471 | December 31, 2018 | July 1, 2021 | July 1, 2021 | October 17, 2018 | February 11, 2019 |
|
|||
12 | NCT03571360 | Not yet recruiting | CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
42 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT03571360 | 2017-000689-30 | September 15, 2018 | January 14, 2021 | July 14, 2021 | June 27, 2018 | August 15, 2018 | ||||
13 | NCT03418844 | Recruiting | Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
480 | Female | 18 Years and older (Adult, Older Adult) | NCT03418844 | VIVROVAIRE TR | VIVROVAIRE TR | May 7, 2018 | February 2020 | February 2020 | February 1, 2018 | January 16, 2019 |
|
||
14 | NCT02385110 | Recruiting | Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT02385110 | 2014-0989 NCI-2015-00526 |
September 23, 2015 | September 2019 | September 2020 | March 11, 2015 | March 5, 2018 |
|
|||
15 | NCT02689219 | Recruiting | Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
58 | All | 18 Years and older (Adult, Older Adult) | NCT02689219 | IUSCC-0568 | March 9, 2016 | December 31, 2018 | December 31, 2019 | February 23, 2016 | February 19, 2018 |
|
|||
16 | NCT03203681 | Recruiting | Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters |
|
|
Interventional |
Phase 4 |
|
Other |
|
|
40 | Male | 18 Years to 55 Years (Adult) | NCT03203681 | 20170462 | October 27, 2017 | December 1, 2019 | April 1, 2020 | June 29, 2017 | January 7, 2019 |
|
|||
17 | NCT02834013 | Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
|
|
Interventional |
Phase 2 |
|
NIH |
|
|
707 | All | 18 Years and older (Adult, Older Adult) | NCT02834013 | NCI-2016-01041 S1609 U10CA180888 |
January 13, 2017 | August 31, 2020 | July 15, 2016 | February 15, 2019 |
|
||||
18 | NCT02662647 | Recruiting | Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
120 | All | 60 Years to 75 Years (Adult, Older Adult) | NCT02662647 | ChinaNGH-H001 | April 2015 | June 2018 | December 2019 | January 25, 2016 | January 26, 2016 |
|
|||
19 | NCT01950156 | Recruiting | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
6 | All | 20 Years to 85 Years (Adult, Older Adult) | NCT01950156 | SUMS-23-57 23-57 |
September 2011 | June 2018 | June 2018 | September 25, 2013 | October 25, 2017 |
|
|||
20 | NCT02650986 | Recruiting | Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1 |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / NIH |
|
|
24 | All | 18 Years and older (Adult, Older Adult) | NCT02650986 | I 258514 NCI-2015-02080 P30CA016056 |
June 30, 2017 | March 20, 2019 | December 20, 2019 | January 8, 2016 | February 7, 2019 |
|
|||
21 | NCT02994758 | Recruiting | Development of Diagnostics and Treatment of Urological Cancers |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Older Adult) | NCT02994758 | None yet | DEDUCER | November 27, 2017 | December 2020 | December 2020 | December 16, 2016 | December 14, 2017 |
|
||
22 | NCT01782339 | Recruiting | A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
43 | All | 16 Years to 65 Years (Child, Adult, Older Adult) | NCT01782339 | 007755 2010-022795-31 |
GAMMA | July 2012 | January 2021 | January 2021 | February 1, 2013 | August 31, 2017 |
|
||
23 | NCT03029273 | Recruiting | NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
20 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03029273 | 2016-63 | March 21, 2017 | March 2019 | March 2019 | January 24, 2017 | January 17, 2019 |
|
|||
24 | NCT03110445 | Not yet recruiting | Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
15 | All | 18 Years and older (Adult, Older Adult) | NCT03110445 | EKNZ 2015-026 | rVV-740CTA | June 2019 | September 2020 | September 2021 | April 12, 2017 | February 15, 2019 | |||
25 | NCT03232541 | Recruiting | The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
288 | All | 18 Years and older (Adult, Older Adult) | NCT03232541 | Emesis 001 | September 1, 2017 | June 2019 | June 2019 | July 28, 2017 | March 29, 2018 |
|
|||
26 | NCT03391232 | Recruiting | PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO) |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry / Other |
|
|
15 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03391232 | OBERTO 101 | OBERTO | April 9, 2018 | April 9, 2019 | December 21, 2019 | January 5, 2018 | September 26, 2018 |
|
||
27 | NCT02775292 | Recruiting | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 |
|
|
Interventional |
Phase 1 |
|
Other / NIH |
|
|
12 | All | 16 Years and older (Child, Adult, Older Adult) | NCT02775292 | 15-001433 NCI-2016-00201 Ribas NYESO + Nivolumab Cancer P30CA016042 |
NYM | January 3, 2017 | June 2019 | June 2019 | May 17, 2016 | July 13, 2018 |
|
||
28 | NCT03799601 | Not yet recruiting | Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC |
|
|
Interventional |
Phase 4 |
|
Other / Industry |
|
|
45 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03799601 | TJCC-LC-20190108 | ALTER-L013 | March 1, 2019 | December 1, 2019 | December 1, 2020 | January 10, 2019 | January 10, 2019 |
|
||
29 | NCT01037790 | Recruiting | PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
205 | All | 18 Years and older (Adult, Older Adult) | NCT01037790 | UPCC 03909 NCI-2009-01467 |
October 2009 | October 2019 | December 23, 2009 | August 22, 2018 |
|
||||
30 | NCT03081923 | Recruiting | Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
120 | Male | 18 Years to 75 Years (Adult, Older Adult) | NCT03081923 | INT123-16 | APACHE | February 1, 2017 | February 2019 | August 2019 | March 16, 2017 | March 16, 2017 |
|
||
31 | NCT02317393 | Recruiting | Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
19 | All | 18 Years and older (Adult, Older Adult) | NCT02317393 | TERMATEP | TERMATEP | December 2014 | March 2020 | March 2020 | December 16, 2014 | January 16, 2019 |
|
||
32 | NCT02784054 | Recruiting | Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
25 | All | 3 Years to 30 Years (Child, Adult) | NCT02784054 | 2013-07-146 | April 2014 | March 2019 | March 2022 | May 26, 2016 | September 18, 2018 |
|
|||
33 | NCT02797626 | Recruiting | Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST) |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
30 | Male | Child, Adult, Older Adult | NCT02797626 | 2015053664 | June 2016 | June 2021 | June 2021 | June 13, 2016 | June 13, 2016 |
|
|||
34 | NCT02582697 | Recruiting | Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
500 | All | 11 Years to 45 Years (Child, Adult) | NCT02582697 | ANZUP1302 ACTRN12613000496718 |
P3BEP | February 2014 | February 2022 | July 2023 | October 21, 2015 | July 11, 2017 |
|
||
35 | NCT02115165 | Recruiting | A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
34 | Male | 15 Years and older (Child, Adult, Older Adult) | NCT02115165 | 2013-000286-36 2012/1950 |
CABA-GCT | May 2014 | May 2017 | May 2020 | April 15, 2014 | June 9, 2016 |
|
||
36 | NCT00432094 | Recruiting | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
25 | All | 10 Years to 69 Years (Child, Adult, Older Adult) | NCT00432094 | 2006LS032 UMN-MT2005-21 UMN-0608M90586 |
December 19, 2006 | January 2020 | January 2020 | February 7, 2007 | February 12, 2019 |
|
|||
37 | NCT03180918 | Recruiting | Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
100 | Male | 3 Months to 18 Years (Child, Adult) | NCT03180918 | PB_2016-01378 | January 2015 | January 2100 | January 2100 | June 8, 2017 | November 6, 2018 |
|
|||
38 | NCT03174275 | Recruiting | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
39 | All | 18 Years and older (Adult, Older Adult) | NCT03174275 | LCCC 1621 | December 19, 2017 | September 1, 2021 | September 1, 2026 | June 2, 2017 | January 29, 2019 |
|
|||
39 | NCT02750995 | Recruiting | Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
15 | All | 18 Years and older (Adult, Older Adult) | NCT02750995 | AZACTA | AZACTA | April 2016 | April 2020 | September 2020 | April 26, 2016 | September 1, 2017 |
|
||
40 | NCT03158064 | Recruiting | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
29 | All | 18 Years and older (Adult, Older Adult) | NCT03158064 | 17-160 | May 15, 2017 | November 2019 | November 2019 | May 17, 2017 | October 24, 2018 |
|
|||
41 | NCT00579514 | Recruiting | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
35000 | All | Child, Adult, Older Adult | NCT00579514 | 00-014 | March 2000 | March 2020 | March 2020 | December 24, 2007 | September 28, 2018 |
|
|||
42 | NCT01042522 | Recruiting | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors |
|
|
Interventional |
Phase 2 |
|
Other / NIH |
|
|
128 | Female | 18 Years and older (Adult, Older Adult) | NCT01042522 | GOG-0264 NCI-2011-02000 CDR0000662814 U10CA180868 U10CA027469 |
February 8, 2010 | January 2, 2024 | January 5, 2010 | February 16, 2018 |
|
||||
43 | NCT02375204 | Recruiting | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors |
|
|
Interventional |
Phase 3 |
|
Other / NIH |
|
|
420 | Male | 14 Years and older (Child, Adult, Older Adult) | NCT02375204 | A031102 U10CA180821 NCI-2014-01696 |
March 2015 | June 2024 | March 2, 2015 | January 24, 2019 |
|
||||
44 | NCT02537548 | Recruiting | Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma |
|
|
Interventional |
Not Applicable |
|
Other / NIH |
|
|
46 | Male | 16 Years and older (Child, Adult, Older Adult) | NCT02537548 | 4T-14-1 NCI-2015-01177 HS-15-00246 P30CA014089 |
August 28, 2015 | August 28, 2019 | August 28, 2020 | September 1, 2015 | July 19, 2018 |
|
|||
45 | NCT02972801 | Recruiting | Testicular Tissue Cryopreservation for Fertility Preservation |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
250 | Male | Child, Adult, Older Adult | NCT02972801 | PRO09120485 | January 2010 | January 2021 | January 2021 | November 23, 2016 | January 3, 2019 |
|
|||
46 | NCT03709550 | Not yet recruiting | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / NIH |
|
|
21 | Male | 18 Years and older (Adult, Older Adult) | NCT03709550 | I 51317 NCI-2018-01755 P30CA016056 |
January 30, 2019 | August 31, 2019 | August 31, 2020 | October 17, 2018 | December 14, 2018 |
|
|||
47 | NCT03504449 | Recruiting | Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
350 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03504449 | SCRM-01 | SCRM-01 | December 1, 2016 | December 1, 2020 | December 1, 2020 | April 20, 2018 | April 20, 2018 |
|
||
48 | NCT03449719 | Not yet recruiting | Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO) |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
174 | Male | Child, Adult, Older Adult | NCT03449719 | ARTO | ARTO | May 1, 2018 | September 1, 2021 | May 1, 2022 | February 28, 2018 | February 28, 2018 |
† Study has passed its completion date and status has not been verified in more than two years.